{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T08:10:07Z","timestamp":1750752607512,"version":"3.41.0"},"reference-count":71,"publisher":"Elsevier","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["CEECINST\/00091\/2018\/CP1500\/CT0020"],"award-info":[{"award-number":["CEECINST\/00091\/2018\/CP1500\/CT0020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.ircmb.2025.01.003","type":"book-chapter","created":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T19:50:09Z","timestamp":1737921009000},"source":"Crossref","is-referenced-by-count":0,"title":["Cytokine-based immunotherapy in hematolymphoid malignancies"],"prefix":"10.1016","author":[{"given":"M\u00e1rio","family":"Sousa-Pimenta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuno R.","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.003_bib1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood.V99.1.67","article-title":"Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma","volume":"99","author":"Ansell","year":"2002","journal-title":"Blood"},{"issue":"22","key":"10.1016\/bs.ircmb.2025.01.003_bib2","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197011262832202","article-title":"Cutaneous interferon production in patients with Hodgkin\u2019s disease and other cancers infected with varicella or vaccinia","volume":"283","author":"Armstrong","year":"1970","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"10.1016\/bs.ircmb.2025.01.003_bib3","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nri3814","article-title":"Germinal centres and B cell lymphomagenesis","volume":"15","author":"Basso","year":"2015","journal-title":"Nature Reviews. Immunology"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.003_bib4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"British Journal of Cancer"},{"issue":"12","key":"10.1016\/bs.ircmb.2025.01.003_bib5","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1182\/blood.2023023529","article-title":"NK cells with adhesion defects and reduced cytotoxic functions are associated with a poor prognosis in multiple myeloma","volume":"144","author":"Blanquart","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/bs.ircmb.2025.01.003_bib6","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1634\/theoncologist.2013-0223","article-title":"A randomized study of interferon \u03b1-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphoma","volume":"18","author":"Bosly","year":"2013","journal-title":"The Oncologist"},{"key":"10.1016\/bs.ircmb.2025.01.003_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.730970","article-title":"Chronic IL-15 stimulation and impaired mTOR signaling and metabolism in natural killer cells during acute myeloid leukemia","volume":"12","author":"Bou-Tayeh","year":"2021","journal-title":"Frontiers in Immunology"},{"issue":"12","key":"10.1016\/bs.ircmb.2025.01.003_bib8","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Casares","year":"2005","journal-title":"The Journal of Experimental Medicine"},{"issue":"11","key":"10.1016\/bs.ircmb.2025.01.003_bib9","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1182\/blood.V112.11.4630.4630","article-title":"RFUSIN2 \u2013 a clinical grade lentiviral vector co-expressing CD80\/IL-2 manufactured under GMP for a phase I clinical trial study of immune gene therapy for poor prognosis acute myeloid leukaemia","volume":"112","author":"Chan","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/bs.ircmb.2025.01.003_bib10","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s44222-023-00030-y","article-title":"Engineering cytokine therapeutics","volume":"1","author":"Deckers","year":"2023","journal-title":"Nature Reviews Bioengineering"},{"issue":"21","key":"10.1016\/bs.ircmb.2025.01.003_bib11","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","article-title":"A history of cancer chemotherapy","volume":"68","author":"DeVita","year":"2008","journal-title":"Cancer Research"},{"issue":"4","key":"10.1016\/bs.ircmb.2025.01.003_bib12","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.4049\/jimmunol.132.4.2123","article-title":"The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma","volume":"132","author":"Donohue","year":"1984","journal-title":"Journal of Immunology (Baltimore, Md.: 1950)"},{"issue":"5","key":"10.1016\/bs.ircmb.2025.01.003_bib13","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jaad.2006.06.038","article-title":"A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides","volume":"55","author":"Duvic","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"10.1016\/bs.ircmb.2025.01.003_bib14","first-page":"385","article-title":"Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2","volume":"156","author":"Eberlein","year":"1982","journal-title":"The Journal of Experimental Medicine"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.003_bib15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1600-065X.2008.00631.x","article-title":"The role of IL-21 in regulating B-cell function in health and disease","volume":"223","author":"Ettinger","year":"2008","journal-title":"Immunological Reviews"},{"issue":"4","key":"10.1016\/bs.ircmb.2025.01.003_bib16","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1189\/jlb.5RU0714-360RR","article-title":"Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP","volume":"97","author":"Fabbi","year":"2015","journal-title":"Journal of Leukocyte Biology"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.003_bib17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nri3567","article-title":"Human memory T cells: Generation, compartmentalization and homeostasis","volume":"14","author":"Farber","year":"2014","journal-title":"Nature Reviews. Immunology"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.003_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/bloodadvances.2022007985","article-title":"Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15","volume":"7","author":"Fernandez","year":"2023","journal-title":"Blood Advances"},{"issue":"12","key":"10.1016\/bs.ircmb.2025.01.003_bib19","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1158\/1078-0432.CCR-20-4575","article-title":"Phase I trial of N-803, an IL15 receptor agonist, with rituximab in patients with indolent non-hodgkin lymphoma","volume":"27","author":"Foltz","year":"2021","journal-title":"Clinical Cancer Research"},{"issue":"11","key":"10.1016\/bs.ircmb.2025.01.003_bib20","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1182\/blood.V99.11.3892","article-title":"Interleukin-7: From bench to clinic","volume":"99","author":"Fry","year":"2002","journal-title":"Blood"},{"issue":"11","key":"10.1016\/bs.ircmb.2025.01.003_bib21","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s00277-014-2135-8","article-title":"Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab","volume":"93","author":"Garc\u00eda Mu\u00f1oz","year":"2014","journal-title":"Annals of Hematology"},{"issue":"3","key":"10.1016\/bs.ircmb.2025.01.003_bib22","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): A randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"The Lancet Haematology"},{"issue":"3","key":"10.1016\/bs.ircmb.2025.01.003_bib23","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.cyto.2011.09.028","article-title":"IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterization","volume":"56","author":"Han","year":"2011","journal-title":"Cytokine"},{"issue":"Supplement 1","key":"10.1016\/bs.ircmb.2025.01.003_bib24","doi-asserted-by":"crossref","first-page":"6824","DOI":"10.1182\/blood-2023-178289","article-title":"CD19-specific CAR NK cells coexpressing IL-21 exhibit superior expansion and antitumor activity against CD19-postive lymphoma","volume":"142","author":"He","year":"2023","journal-title":"Blood"},{"issue":"17","key":"10.1016\/bs.ircmb.2025.01.003_bib25","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.003_bib26","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/imm.12913","article-title":"T-cell modulation by cyclophosphamide for tumour therapy","volume":"154","author":"Hughes","year":"2018","journal-title":"Immunology"},{"issue":"25","key":"10.1016\/bs.ircmb.2025.01.003_bib27","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMp1113569","article-title":"The burden of disease and the changing task of medicine","volume":"366","author":"Jones","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1016\/bs.ircmb.2025.01.003_bib28","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41375-022-01528-x","article-title":"Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b","volume":"36","author":"Kiladjian","year":"2022","journal-title":"Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U. K"},{"issue":"7","key":"10.1016\/bs.ircmb.2025.01.003_bib29","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12032-024-02404-7","article-title":"From bench to bedside: The past, present and future of IL-21 immunotherapy","volume":"41","author":"Kim","year":"2024","journal-title":"Medical Oncology"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.003_bib30","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13045-022-01382-5","article-title":"Natural killer cells in clinical development as non-engineered, engineered, and combination therapies","volume":"15","author":"Lamers-Kok","year":"2022","journal-title":"Journal of Hematology & Oncology"},{"issue":"8","key":"10.1016\/bs.ircmb.2025.01.003_bib31","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1182\/blood-2008-01-134783","article-title":"Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3\u03b1","volume":"112","author":"Lamprecht","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.003_bib32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41584-023-01053-w","article-title":"Biological and clinical roles of IL-18 in inflammatory diseases","volume":"20","author":"Landy","year":"2024","journal-title":"Nature Reviews Rheumatology"},{"issue":"22","key":"10.1016\/bs.ircmb.2025.01.003_bib33","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1182\/blood.V128.22.620.620","article-title":"DI-Leu16-IL2, an anti-CD20-interleukin-2 immunocytokine, is safe and active in patients with relapsed and refractory B-cell lymphoma: A report of maximum tolerated dose, optimal biologic dose, and recommended phase 2 dose","volume":"128","author":"Lansigan","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2025.01.003_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02061","article-title":"The dual nature of type I and type II interferons","volume":"9","author":"Lee","year":"2018","journal-title":"Frontiers in Immunology"},{"issue":"2","key":"10.1016\/bs.ircmb.2025.01.003_bib35","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/cid\/cis383","article-title":"Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: Results of a phase I\/IIa randomized, placebo-controlled, multicenter study","volume":"55","author":"L\u00e9vy","year":"2012","journal-title":"Clinical Infectious Diseases"},{"issue":"5","key":"10.1016\/bs.ircmb.2025.01.003_bib36","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1016\/j.transproceed.2005.03.088","article-title":"Antileukemic effect of interleukin-7-transduced bone marrow stromal cells in mice following allogeneic T-cell-depleted bone marrow transplantation","volume":"37","author":"Li","year":"2005","journal-title":"Transplantation Proceedings"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.003_bib37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.immuni.2013.01.004","article-title":"Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy","volume":"38","author":"Liao","year":"2013","journal-title":"Immunity"},{"issue":"46","key":"10.1016\/bs.ircmb.2025.01.003_bib38","doi-asserted-by":"crossref","first-page":"23869","DOI":"10.1074\/jbc.M116.733600","article-title":"A novel fusion of ALT-803 (interleukin (IL)-15 superagonist) with an antibody demonstrates antigen-specific antitumor responses","volume":"291","author":"Liu","year":"2016","journal-title":"Journal of Biological Chemistry"},{"issue":"20","key":"10.1016\/bs.ircmb.2025.01.003_bib39","doi-asserted-by":"crossref","first-page":"6471","DOI":"10.1073\/pnas.81.20.6471","article-title":"Remission of leukemia and loss of feline leukemia virus in cats injected with Staphylococcus protein A: Association with increased circulating interferon and complement-dependent cytotoxic antibody","volume":"81","author":"Liu","year":"1984","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"4","key":"10.1016\/bs.ircmb.2025.01.003_bib40","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1158\/2326-6066.CIR-22-0398","article-title":"IL18 receptor signaling regulates tumor-reactive CD8+ T-cell exhaustion via activation of the IL2\/STAT5\/mTOR pathway in a pancreatic cancer model","volume":"11","author":"Lutz","year":"2023","journal-title":"Cancer Immunology Research"},{"issue":"8","key":"10.1016\/bs.ircmb.2025.01.003_bib41","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.4049\/jimmunol.170.8.4111","article-title":"IL-21 induces the apoptosis of resting and activated primary B cells","volume":"170","author":"Mehta","year":"2003","journal-title":"The Journal of Immunology"},{"issue":"3","key":"10.1016\/bs.ircmb.2025.01.003_bib42","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/bloodadvances.2021006440","article-title":"Interleukin-15 augments NK cell\u2013mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies","volume":"7","author":"Miljkovic","year":"2023","journal-title":"Blood Advances"},{"issue":"2","key":"10.1016\/bs.ircmb.2025.01.003_bib43","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nature Reviews. Immunology"},{"issue":"5","key":"10.1016\/bs.ircmb.2025.01.003_bib44","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1056\/NEJMra1201534","article-title":"Measuring the global burden of disease","volume":"369","author":"Murray","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"24","key":"10.1016\/bs.ircmb.2025.01.003_bib45","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1182\/blood-2012-06-437236","article-title":"Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation","volume":"120","author":"Perales","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/bs.ircmb.2025.01.003_bib46","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1182\/blood.V68.2.493.493","article-title":"Treatment of hairy cell leukemia with recombinant \u03b1-interferon","volume":"68","author":"Quesada","year":"1986","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2025.01.003_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104539","article-title":"A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases","volume":"90","author":"Raeber","year":"2023","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/bs.ircmb.2025.01.003_bib48","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1182\/blood-2005-01-0201","article-title":"Impaired interferon-\u03b3 production as a consequence of STAT4 deficiency after autologous hematopoietic stem cell transplantation for lymphoma","volume":"106","author":"Robertson","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/bs.ircmb.2025.01.003_bib49","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/CJI.0b013e31829d7e2e","article-title":"A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-Hodgkin lymphoma","volume":"36","author":"Robertson","year":"2013","journal-title":"Journal of Immunotherapy"},{"issue":"3","key":"10.1016\/bs.ircmb.2025.01.003_bib50","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/CJI.0000000000000220","article-title":"A dose-escalation study of recombinant human interleukin-18 in combination with ofatumumab after autologous peripheral blood stem cell transplantation for lymphoma","volume":"41","author":"Robertson","year":"2018","journal-title":"Journal of Immunotherapy"},{"issue":"23","key":"10.1016\/bs.ircmb.2025.01.003_bib51","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood-2017-12-823757","article-title":"First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation","volume":"131","author":"Romee","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.ircmb.2025.01.003_bib52","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1182\/blood.V94.3.902.415k23_902_908","article-title":"Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses","volume":"94","author":"Rook","year":"1999","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2025.01.003_bib53","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1749-6632.2001.tb03721.x","article-title":"The role for interleukin-12 therapy of cutaneous T cell lymphoma","volume":"941 (1)","author":"Rook","year":"2001","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"8","key":"10.1016\/bs.ircmb.2025.01.003_bib54","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1182\/blood-2015-05-645077","article-title":"Administration of interleukin-7 increases CD4 T cells in idiopathic CD4 lymphocytopenia","volume":"127","author":"Sheikh","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2025.01.003_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1141208","article-title":"The role of interleukin-15 in the development and treatment of hematological malignancies","volume":"14","author":"Sindaco","year":"2023","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.003_bib56","doi-asserted-by":"crossref","DOI":"10.1093\/discim\/kyae002","article-title":"Signalling mechanisms driving homeostatic and inflammatory effects of interleukin-15 on tissue lymphocytes","volume":"3","author":"Skariah","year":"2024","journal-title":"Discovery Immunology"},{"issue":"4","key":"10.1016\/bs.ircmb.2025.01.003_bib57","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.4049\/jimmunol.0903210","article-title":"IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-\u03b3\u2013dependent mechanisms","volume":"184","author":"Sorensen","year":"2010","journal-title":"The Journal of Immunology"},{"issue":"5","key":"10.1016\/bs.ircmb.2025.01.003_bib58","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrd4296","article-title":"Interleukin-21: A double-edged sword with therapeutic potential","volume":"13","author":"Spolski","year":"2014","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"4","key":"10.1016\/bs.ircmb.2025.01.003_bib59","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.immuni.2019.03.011","article-title":"The immunobiology of the interleukin-12 family: Room for discovery","volume":"50","author":"Tait Wojno","year":"2019","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/bs.ircmb.2025.01.003_bib60","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.3324\/haematol.13074","article-title":"The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders","volume":"93","author":"Theocharides","year":"2008","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/bs.ircmb.2025.01.003_bib61","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1158\/1078-0432.CCR-12-0456","article-title":"A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders","volume":"18","author":"Timmerman","year":"2012","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.ircmb.2025.01.003_bib62","first-page":"1563","article-title":"Immunology of IL-12: An update on functional activities and implications for disease","volume":"19","author":"Ullrich","year":"2020","journal-title":"EXCLI Journal"},{"key":"10.1016\/bs.ircmb.2025.01.003_bib63","doi-asserted-by":"crossref","DOI":"10.1177\/20406207241229588","article-title":"Interferons in the treatment of myeloproliferative neoplasms","volume":"15","author":"Vachhani","year":"2024","journal-title":"Therapeutic Advances in Hematology"},{"issue":"Supplement 1","key":"10.1016\/bs.ircmb.2025.01.003_bib64","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1182\/blood-2021-150750","article-title":"A phase I clinical trial testing the safety of IL-21-expanded, universally alloreactive donor-derived natural killer cells for relapsed\/refractory acute myeloid leukemia and myelodysplastic syndrome","volume":"138","author":"Vasu","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/bs.ircmb.2025.01.003_bib65","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41577-020-00457-z","article-title":"T cell regeneration after immunological injury","volume":"21","author":"Velardi","year":"2021","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/bs.ircmb.2025.01.003_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.779865","article-title":"The half-life-extended IL21 can be combined with multiple checkpoint inhibitors for tumor immunotherapy","volume":"9","author":"Wu","year":"2021","journal-title":"Frontiers in Cell and Developmental Biology"},{"issue":"10","key":"10.1016\/bs.ircmb.2025.01.003_bib67","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1158\/0008-5472.CAN-12-2357","article-title":"Efficacy and mechanism-of-action of a novel superagonist interleukin-15: Interleukin-15 receptor \u03b1Su\/Fc fusion complex in syngeneic murine models of multiple myeloma","volume":"73","author":"Xu","year":"2013","journal-title":"Cancer Research"},{"issue":"16","key":"10.1016\/bs.ircmb.2025.01.003_bib68","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1158\/1078-0432.CCR-04-0540","article-title":"Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin\u2019s lymphoma and Hodgkin\u2019s disease","volume":"10","author":"Younes","year":"2004","journal-title":"Clinical Cancer Research"},{"issue":"S 1","key":"10.1016\/bs.ircmb.2025.01.003_bib69","first-page":"23","article-title":"Pharmacokinetics of peginterferons","volume":"23","author":"Zeuzem","year":"2003","journal-title":"Seminars in Liver Disease"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.003_bib70","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","article-title":"Global burden of hematologic malignancies and evolution patterns over the past 30 years","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer Journal"},{"issue":"17","key":"10.1016\/bs.ircmb.2025.01.003_bib71","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.3390\/cancers14174160","article-title":"Tumor infiltrating lymphocyte (TIL) therapy for solid tumor treatment: Progressions and challenges","volume":"14","author":"Zhao","year":"2022","journal-title":"Cancers"}],"container-title":["International Review of Cell and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644825000036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644825000036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T07:36:38Z","timestamp":1750750598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1937644825000036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":71,"URL":"https:\/\/doi.org\/10.1016\/bs.ircmb.2025.01.003","relation":{},"ISSN":["1937-6448"],"issn-type":[{"type":"print","value":"1937-6448"}],"subject":[],"published":{"date-parts":[[2025]]}}}